Actively Recruiting
Pharmacogenomics of Heparin-Induced Thrombocytopenia
Led by University of Arizona · Updated on 2024-06-27
125
Participants Needed
1
Research Sites
539 weeks
Total Duration
On this page
Sponsors
U
University of Arizona
Lead Sponsor
A
American College of Clinical Pharmacy
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.
CONDITIONS
Official Title
Pharmacogenomics of Heparin-Induced Thrombocytopenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Ability to give informed consent
- Have undergone testing for heparin/PF4 antibody with or without SRA testing for HIT
- Have received treatment with unfractionated heparin or low molecular weight heparin (enoxaparin, dalteparin, tinzaparin) prior to antibody or SRA testing
You will not qualify if you...
- Less than 18 years of age
- Pregnancy
- Hemoglobin less than 9 mg/dL (for larger 5 ounce blood draw)
- Known Human Immunodeficiency Virus (HIV) infection
- Inability to give informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Banner University Medical Center - Tucson
Tucson, Arizona, United States, 85721
Actively Recruiting
Research Team
J
Jason H Karnes, PharmD, PhD
CONTACT
T
Talin A Robinson-Catalan, MS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here